Sutro Biopharma STRO Interest And Other Income Expense Net
Interest And Other Income Expense Net at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:InterestAndOtherIncomeExpenseNet.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's interest and other income expense net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's interest and other income expense net?
- Sutro Biopharma (STRO) reported interest and other income expense net of -$1.01M in Q1 2026.
- How has Sutro Biopharma's interest and other income expense net changed year-over-year?
- Sutro Biopharma's interest and other income expense net increased by 21.7% year-over-year, from -$1.29M to -$1.01M.
- What is the long-term trend for Sutro Biopharma's interest and other income expense net?
- Over 3 years (2021 to 2025), Sutro Biopharma's interest and other income expense net has grown at a 7.1% compound annual growth rate (CAGR), from -$3.14M to -$3.86M.
- What does interest and other income expense net mean?
- This metric captures the net balance of interest income, interest expense, and other miscellaneous non-operating financial gains or losses. It provides a comprehensive view of the company's peripheral financial activities that are not directly tied to core drug discovery and manufacturing operations. A net positive value indicates that financial income exceeds costs, while a net negative value indicates a drag on the bottom line from non-operating items.